First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings
Completed · Not applicable
Conditions studied: End Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Kidney Disease
In brief
This is a non-significant risk study utilizing a device cleared for use by the FDA under its 510(k) clearance. Consented patients will complete their usual dialysis treatment under professional care in an ICHD (In-Center Hemodialysis) setting.
Key facts
- Study ID
- NCT06581393
- Run by
- Diality Inc.
- People needed
- 12
- Starts
- 2024-12-09
- Expected to finish
- 2025-04-28
- Last updated by the study team
- 2025-06-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Have a diagnosis of end stage kidney disease (ESKD) adequately treated by maintenance dialysis (defined as achieving a spKt/V ≥ 1.2 OR stdKt/V ≥ 2.1) and be deemed stable by their treating nephrologist prior to consent.
- Must sign the informed consent and a Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant authorization statement.
- Understand the nature of the procedures and the requirements of the Study.
You may not qualify if…
- Have a significant cognitive impairment that would preclude informed consent or the capacity for completing dialysis as prescribed by their treating nephrologist.
- In the opinion of the treating nephrologist, any other reason in which study participation would result in undue risk, including but not limited to protocol required prescription parameters.
- Are contraindicated for or not indicated to use the Moda-flx Hemodialysis System™ according to the Instructions For Use (IFU).
Where it is running
- North America Research Institute — Ontario, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.